Scientists are betting they can treat aging as a medical condition, not an inevitable fact of life. Yet longevity clinics are multiplying around the world, and new medical frameworks are taking shape. Who’ll get access to these interventions? And could they widen health inequality?
Daniel Belsky, associate professor of epidemiology at the Columbia University Mailman School of Public Health and the Robert N. Butler Columbia Aging Center, put the vision plainly: “We don't know yet whether we can really do this. But we do have an alignment of evidence to argue this is possible. And we now have a mobilization of resources to actually test it.” The idea calls for a radical shift in medical thinking. Instead of waiting for diabetes, cardiovascular disease, or cancer to appear and treating each separately, researchers argue that medicine could target the biological aging processes themselves—the cellular changes that drive several diseases at once.
Nir Barzilai, director of the institute for aging research at Albert Einstein College of Medicine in New York City, put it directly: “Aging has biology. This biology drives diseases.” Lab studies have shown promise. Medicines, exercise, calorie restriction, and other interventions can slow cellular aging and extend the lives of roundworms and mice. Humans, though, remain uncharted territory. “For humans, we do not yet have clinical trial evidence that intervention on this biology to extend health span is possible,” Belsky said.
The Emerging Field and Its Gaps
Researchers are developing ways to measure biological aging that go beyond chronological age. Epigenetics—changes in how genes are regulated without altering DNA itself—offers one path. Belsky said chemical tags called methyl groups bonded to DNA “could track the passage of time in a human body.” His Finding Aging Biomarkers by Searching Existing Trials (FAST) project gathers multi-omic data from white blood cells, studying proteins, metabolites, and epigenetic marks to identify which respond to interventions.
A major gap remains. Researchers haven't established whether changing those biomarkers actually extends healthy human lifespan. The effects could take decades to show up. A trial testing whether an intervention started at age 40 or 50 could prevent chronic disease might need to track participants for two or three decades. Researchers are considering whether aging biomarkers could act as “surrogate endpoint[s]” in clinical trials, enabling faster judgments about whether an intervention may work, if those markers reliably predict long-term disease prevention.
Longevity Clinics and the Regulation Question
Longevity clinics are opening around the world, offering standard medical assessments alongside extensive testing to build detailed health profiles. Mayo Clinic launched its Healthy Longevity Clinic in 2023, three years elapsed as of now. Singapore's National University Health System set up a similar program that pairs detailed assessments with personalized lifestyle and medical interventions. But the field has grown faster than oversight. Some scientists have warned that it needs better regulation as clinics become more common.
Abu Dhabi moved first. In October 2024, approximately one year elapsed, the Department of Health introduced a licensing framework for Healthy Longevity Medicine Centers. The department called it the first of its kind globally, defining a clinical category and setting standards for facilities. Under the framework, the Institute for Healthier Living Abu Dhabi became the world's first state-designated specialized Healthy Longevity Medicine Center.
Allan Boston, the institute's chief operating officer, described the shift in thinking: “All your cells are aging constantly. In the past, we thought that was just an inevitable stage of life. It's not inevitable. There are things we can now start to do about that. That changes the whole concept of medicine.” He outlined the possibilities: “The more we understand that cellular level activity, the more we can design therapies, drugs, other immunotherapies, technologies that can alter that pathway, slow it down and even potentially reverse it.”
The Accessibility Question
Here the center-left concern comes into sharper focus. Specialized longevity medicine takes resources: comprehensive testing, expert assessment, and potentially costly interventions. These clinics aren't opening in underserved communities or countries with limited health infrastructure. They're appearing in wealthy medical centers and wealthy nations. Who benefits?
Belsky offered an equity-focused counterpoint. “Sleep, exercise, community and diet can help influence the biology of aging without advanced medical innovations or specialist clinics,” he said. “The thing we know works is available in some form to most of us. These are things where almost all of us can make progress. We can add healthy years to our lifespan even without these new drugs.”
That difference matters enormously. The science itself suggests proven measures—sleep, movement, social connection, and nutrition—don't require pricey clinics or pharmaceutical breakthroughs. Yet the resources Belsky described, the opening of specialized centers, and new regulatory frameworks are gathering around medical solutions rather than public health. This follows a familiar pattern: medicine addresses problems through individualized clinical care for people who can access and afford it, rather than systemic changes that support health across communities.
Why This Matters:
Longevity medicine marks a genuine scientific frontier with real potential to improve people's lives. But its path so far—specialized clinics in wealthy cities, regulatory frameworks that legitimize clinical approaches, and investment focused on medical interventions—risks widening health inequality. Those most likely to get access to advanced aging interventions are people already advantaged by wealth and geography. Meanwhile, evidence suggests the strongest tools for extending healthy years—sleep, exercise, community ties, and adequate nutrition—remain unevenly distributed across society.
A center-left perspective recognizes this tension. Public policy should ensure universal access to proven interventions: support sleep through labor standards and safe housing, make exercise possible through public parks and transportation infrastructure, strengthen community with investment in public gathering spaces, and guarantee nutrition through food security programs. The emerging field of longevity medicine shouldn't displace those basic commitments. If anything, the science makes them more urgent.